Center for Novel Drug Delivery Systems, Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, N. P. Marg, Matunga, Mumbai, India.
AAPS PharmSciTech. 2012 Mar;13(1):254-61. doi: 10.1208/s12249-011-9748-1. Epub 2012 Jan 10.
Surmounting the constraints of limited solubilization efficiency and prime requisite of antioxidant for conventional lipid formulations, the research work explores an edge over formulation utilizing potential applicability of rice germ oil (RGO) as a multifunctional excipient. Self-microemulsifying drug delivery system (SMEDDS) of tacrolimus (TAC) was formulated with RGO, an indigenous source of gamma-oryzanol. Being the same biological source, RGO and rice bran oil (RBO) were compared and it was found that RGO have more solubilization potential for TAC (2.2-fold) as well as higher antioxidant activity (8.06-fold) than the RBO. TAC-SMEDDS was prepared using RGO/Capmul PG8 (2:3) as an oil phase, Cremophore EL as a surfactant, and Transcutol P as a cosurfactant. The approximate particle size of TAC-SMEDDS was found to be 38 nm by dynamic light scattering and 12 nm by small angle neutron scattering. The in vitro dissolution studies showed complete and rapid drug release in 30 min compared to a plain drug (<5%) and marketed capsule (<50%). AUC and C(max) were found to be 45.05 ± 15.64 ng h/ml and 3.91 ± 1.2 ng/ml for TAC-SMEDDS, 12.59 ± 5.54 ng h/ml and 0.48 ± 0.12 ng/ml for plain TAC, and 30.23 ± 10.34 ng h/ml and 2.31 ± 0.68 ng/ml for marketed formulation, respectively. The improved pharmacokinetic profile of TAC-SMEDDS is correlating to the dissolution results. Thus, gamma-oryzanol-enriched RGO acts as a potential multifunctional excipient for lipid formulations.
克服有限的增溶效率限制和传统脂质制剂对抗氧化剂的基本要求,本研究工作探索了利用米胚油(RGO)作为多功能赋形剂的潜在适用性的优势。利用 RGO(γ-谷维素的天然来源),将他克莫司(TAC)的自微乳给药系统(SMEDDS)进行了制剂研究。RGO 和米糠油(RBO)来自同一生物源,对两者进行了比较,结果发现 RGO 对 TAC 的增溶潜力(2.2 倍)和抗氧化活性(8.06 倍)均高于 RBO。TAC-SMEDDS 采用 RGO/Capmul PG8(2:3)作为油相,Cremophor EL 作为表面活性剂,Transcutol P 作为助表面活性剂制备。通过动态光散射法测定 TAC-SMEDDS 的近似粒径为 38nm,通过小角中子散射法测定粒径为 12nm。体外溶出度研究表明,与普通药物(<5%)和市售胶囊(<50%)相比,TAC-SMEDDS 在 30 分钟内可完全快速释放药物。TAC-SMEDDS 的 AUC 和 Cmax 分别为 45.05±15.64ng·h/ml 和 3.91±1.2ng/ml,普通 TAC 分别为 12.59±5.54ng·h/ml 和 0.48±0.12ng/ml,市售制剂分别为 30.23±10.34ng·h/ml 和 2.31±0.68ng/ml。TAC-SMEDDS 的药代动力学改善与溶出度结果相关。因此,富含γ-谷维素的 RGO 可作为脂质制剂的潜在多功能赋形剂。